Log in

Relevant bibliographies by topics / 342.25: 35.076.12(043.2)

Contents

Journal articles

Academic literature on the topic '342.25: 35.076.12(043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '342.25: 35.076.12(043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "342.25: 35.076.12(043.2)"

1

Li, Bing, Jinqin Liu, Shiqiang Qu, et al. "Colony-Forming Unit Cell (CFU-C) Assays in Myelodysplastic Syndrome." Blood 126, no. 23 (2015): 2874. http://dx.doi.org/10.1182/blood.v126.23.2874.2874.

Full text

Abstract:

Abstract Introduction: The myelodysplastic syndromes (MDS) are a group of clonal diseases derived from hematopoietic stem cells (HSC). Colony-forming unit cell (CFU-C) assay is an effective method to study the number and the function of HSC in vitro. In this study, we focus on the characteristics and the prognostic value of CFU-C in patients with MDS. Patients and Method: CFU-C assays were performed according to the protocol of MethoCultTM H4435 Enriched (STEMCELL Technologies). A colony was defined as an aggregate of >40 cells. Clusters consisted of 4 to 40 cells. 560 consecutive newly-dia

APA, Harvard, Vancouver, ISO, and other styles

2

Abu-Khalaf, Maysa, Fnu Nikita, Ayako Shimada, et al. "Abstract P4-11-32: Change in body mass index in breast cancer survivors." Cancer Research 82, no. 4_Supplement (2022): P4–11–32—P4–11–32. http://dx.doi.org/10.1158/1538-7445.sabcs21-p4-11-32.

Full text

Abstract:

Abstract Background: Obesity is associated with an increased risk of breast cancer recurrence and poor survival. Obesity rate in adults in the city of Philadelphia is high, with non-Hispanic blacks and Hispanics having the highest rates. We sought to evaluate changes in body mass index (BMI) in breast cancer survivors within the first 2 years from initial encounter for a breast cancer (BC) diagnosis (dx), and investigate factors that may correlate with a change in BMI. Methods: We identified 5,423 BC patients (pts) in our electronic medical record, (1/2015-present), using ICD-10 code C50.X. We

APA, Harvard, Vancouver, ISO, and other styles

3

Oran, Betul, Richard E. Champlin, Jorge E. Cortes, et al. "Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation." Blood 124, no. 21 (2014): 2531. http://dx.doi.org/10.1182/blood.v124.21.2531.2531.

Full text

Abstract:

Abstract Presence of internal tandem duplication in the FMS-like tyrosine kinase 3 gene(s) (FLT3-ITD) is associated with poor outcome among patients with cytogenetically normal acute myelogenous leukemia (CN-AML). Patients carrying a higher FLT3-ITD allelic burden have worse outcome. Allogeneic stem cell transplantation (SCT) in first remission (CR1) is reported to improve survival in this poor risk patients. We investigated the impact of FLT3-ITD allelic burden, number of FLT3-ITD mutations and SCT with a matched related or unrelated donor in CR1 in newly diagnosed FLT3-ITD mutated intermedia

APA, Harvard, Vancouver, ISO, and other styles

4

Glueck, C. J., H. I. Glueck, L. Mieczkowski, T. Tracy, J. Speirs, and D. Stroop. "Familial High Plasminogen Activator Inhibitor with Hypofibrinolysis, a New Pathophysiologic Cause of Osteonecrosis?" Thrombosis and Haemostasis 69, no. 05 (1993): 460–65. http://dx.doi.org/10.1055/s-0038-1651633.

Full text

Abstract:

SummaryIn a 29 year old white male with osteonecrosis of both hips and a shoulder, and in his family, we measured basal and stimulated (10 min cuff venous occlusion at 100 mgHg) fibrinolytic activity to determine whether low fibrinolytic activity might be heritable and etiologically associated with osteonecrosis. The proband’s basal tPA-Fx was low, 0.08 IU/ml (normal 0.11-1.94), tPA-Ag was normal (11.6 ng/ml), plasminogen activator inhibitor activity (PAI-Fx) was very high, 119 U/ml (normal 3.5-27), as was his plasminogen activator inhibitor antigen (PAI-Ag), 202 ng/ml (normal 3.2-37.1). The p

APA, Harvard, Vancouver, ISO, and other styles

5

Rabaglio, Manuela, Daniel Dietrich, Bernhard Scheibe, et al. "Abstract P4-01-25: Safety analysis after 11 years of follow-up of the randomized phase III trial SAKK22/99: upfront chemotherapy in advanced HER2 positive breast cancer." Cancer Research 83, no. 5_Supplement (2023): P4–01–25—P4–01–25. http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-01-25.

Full text

Abstract:

Abstract Background: The SAKK 22/99 is a phase III randomized clinical trial launched by the Swiss Group for Clinical Cancer Research and the European Institute of Oncology in Milan in 99 for women with HER2-positive advanced breast cancer (ABC). 175 patients were randomized 1:1 from Sept 99 to Jan 2013 to receive first-line trastuzumab (T) alone followed at disease progression by the combination with chemo (Arm A) vs the upfront combination of T and chemo (Arm B). The results were published in 2017 (O. Pagani et al Ann Onc 28: 305–312, 2017). The outcome was similar for sequential T-chemo or

APA, Harvard, Vancouver, ISO, and other styles

6

Fahey, Margaret C., Marion E. Hare, Gerald W. Talcott, et al. "Characteristics Associated With Participation in a Behavioral Weight Loss Randomized Control Trial in the U.S. Military." Military Medicine 184, no. 3-4 (2018): e120-e126. http://dx.doi.org/10.1093/milmed/usy199.

Full text

Abstract:

Abstract Introduction Effective recruitment and subsequent enrollment of diverse populations is often a challenge in randomized controlled trials, especially those focused on weight loss. In the civilian literature, individuals identified as racial and ethnic minorities, men, and younger and older adults are poorly represented in weight loss interventions. There are limited weight loss trials within military populations, and to our knowledge, none reported participant characteristics associated with enrollment. There may be unique motives and barriers for active duty personnel for enrollment i

APA, Harvard, Vancouver, ISO, and other styles

7

Sasaki, Koji, Ildefonso Ismael Rodriguez-Rivera, Hagop M. Kantarjian, et al. "Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase." Blood 124, no. 21 (2014): 4538. http://dx.doi.org/10.1182/blood.v124.21.4538.4538.

Full text

Abstract:

Abstract Background: Total lymphocyte count (TLC) has been shown to correlate with outcomes in patients (pts) with acute leukemia. The clinical correlation to TLC in pts with chronic myeloid leukemia in chronic phase (CML-CP) who were treated with a tyrosine-kinase inhibitor (TKI) is unclear. Methods: Lymphocyte data in pts with newly diagnosed CML-CP who were enrolled in consecutive or parallel clinical trials with front-line imatinib (IM), nilotinib (Nilo), or dasatinib (Dasa) were collected at the time of diagnosis, and 3 and 6 months (M) after the start of TKI. Relative lymphocytrosis (RLC

APA, Harvard, Vancouver, ISO, and other styles

8

Arora, Sankalp, Musa Yilmaz, Wei-Ying Jen, et al. "Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3-Tyrosine Kinase Domain (TKD) Mutations." Blood 144, Supplement 1 (2024): 841. https://doi.org/10.1182/blood-2024-204042.

Full text

Abstract:

Background: FLT3-TKD mutations are present in 7-10% of newly diagnosed AML. However, its prognostic impact remains poorly defined, especially in the current treatment landscape, wherein FLT3-inhibitors (FLT3i) and venetoclax (VEN) are often used in frontline regimens. In one of the largest contemporary series, we describe the characteristics and outcomes of frontline FLT3-TKD AML, including impact of frontline treatment and allogeneic stem cell transplant (allo SCT). Methods: Retrospective analysis including all pts with AML who received frontline AML therapy at MDACC, Houston from 01/2012 - 1

APA, Harvard, Vancouver, ISO, and other styles

9

Van Weelderen, Romy E., Kim Klein, Bianca F. Goemans, et al. "Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG." Blood 136, Supplement 1 (2020): 26–27. http://dx.doi.org/10.1182/blood-2020-136064.

Full text

Abstract:

Introduction Outcome of KMT2A-rearranged (KMT2A-r) pediatric AML (pAML) is in general poor with a 5-year probability of event-free survival (5y-pEFS) and overall survival (5y-pOS) of 44% and 56%, respectively (Balgobind et al., 2009). However, over the past decades, the heterogeneity of KMT2A-r pAML has emerged, showing differences in outcome between subgroups based on translocation partners. The predictive value of MRD in KMT2A-r pAML is undefined. This retrospective study aimed to confirm the outcome of pediatric KMT2A subgroups (Balgobind et al., 2009) in a more recent era and to study the

APA, Harvard, Vancouver, ISO, and other styles

10

Vachhani, Pankit, Jennifer Repp, JE Hamer-Maansson, Evan M. Braunstein, Valkal Bhatt, and Haifa Kathrin Al-Ali. "Clinical Outcomes in Patients with Myelofibrosis Treated with Ruxolitinib and Anemia-Supporting Medications." Blood 144, Supplement 1 (2024): 4546. https://doi.org/10.1182/blood-2024-203924.

Full text

Abstract:

Introduction: Patients with myelofibrosis (MF) often present with anemia, and dose-dependent anemia is a known consequence of treatment with the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib. Current guidelines recommend erythropoiesis-stimulating agents (ESAs) and danazol as options to manage anemia in this population. However, data are lacking regarding the clinical outcomes of patients with MF treated with ruxolitinib and these agents. This post hoc analysis of the phase 3 JUMP trial, the largest ruxolitinib trial to date, evaluated treatment patterns and clinical outcomes of ruxolitinib-t

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!